Tonix is a biopharmaceutical company with a development portfolio focused on central nervous system disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and acute stress disorder (ASD). Although CNS is our primary focus, Tonix’s pipeline is also comprised of immunology, rare disease, and infectious disease product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Our rare disease portfolio includes therapeutics to treat rare genetic conditions including Prader-Willi syndrome, for which we have received FDA Orphan Drug Designation.